FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series A / Biotech startups that raised Series A in Asia

Biotech startups that raised Series A in Asia

Updated 16 Nov 2026

Reset
Biotech startups that raised Series A in Asia
One-time CSV
  • 721 funded companies, 456 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-a~asia.csv721 rows × 18 columns
CompanyCityLast roundAmountDate
altMBangaloreSeries A$10.3M2026-11-05
ApollonSeoulSeries A$3.7M2026-09-22
RemepyRamat GanSeries A$36.0M2026-08-12
Phil Rivers TechnologyBeijingSeries A$29.6M2026-08-05
Tianhu TechnologyMinhangSeries A$29.0M2026-07-13
SynMetaBioShanghaiSeries A$14.7M2026-07-06
Prime LifescienceHangzhouSeries A$14.7M2026-06-30
Lingtai Krypton BiotechnologyShuangliuSeries A$13.7M2026-06-26

8 rows of the CSV in 5 of its 18 columns.

721
Startups
$7.9B
Total raised
127
Funded in the last 12 months
$1.6B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 721
30 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
altM altM is an alternate materials company. Biotech Bangalore, India Series A $10.3M 2026-11-05 $13.8M Omnivore, Theia Ventures, Thai Wah Ventures 11 to 50 2022
Apollon Apollon develops noninvasive continuous glucose monitoring systems. Artificial intelligence Seoul, South Korea Series A $3.7M 2026-09-22 $6.4M TIPS Program, KB Investment, TheVentures +2 11 to 50 2021
Remepy Remepy develops hybrid drugs that combine multiple therapeutic approaches for biotechnology research. Artificial intelligence Ramat Gan, Israel Series A $36.0M 2026-08-12 $51.0M Samsung NEXT, NFX, Vine Ventures +2 11 to 50 2022
Phil Rivers Technology Phil Rivers Technology provides AI solutions for pharmaceutical research and development. Artificial intelligence Beijing, China Series A $29.6M 2026-08-05 $57.3M Insight Capital 51 to 100 2015
Tianhu Technology Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. Artificial intelligence Minhang, China Series A $29.0M 2026-07-13 $54.2M Qiming Venture Partners, GSR United Capital, 3E Bioventures 11 to 50 2021
SynMetaBio SynMetaBio develops synthetic biological materials by combining synthetic biology with material design. Biotech Shanghai, China Series A $14.7M 2026-07-06 $16.1M MiraclePlus, Linear Capital, Danen Capital 11 to 50 2021
Prime Lifescience Prime Lifescience develops a big data platform for life sciences research and analysis. Biotech Hangzhou, China Series A $14.7M 2026-06-30 $44.5M Qiming Venture Partners, Qiji Investment, Ennovation Ventures 11 to 50 2021
Lingtai Krypton Biotechnology Lingtai Krypton Biotechnology develops lncRNA drugs to treat human diseases. Biotech Shuangliu, China Series A $13.7M 2026-06-26 $13.7M Legend Capital, Guosheng Capital, Firefly Haoyue 11 to 50 2021
Artivila Therapeutics Artivila Therapeutics uses artificial intelligence to discover new pharmaceutical drugs for patients. Artificial intelligence Shenzhen, China Series A $14.7M 2026-06-23 $53.3M Highlight Capital, Med-Fine Capital, Hike Capital +2 11 to 50 2018
MoleculeMind MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. Artificial intelligence Haidian, China Series A $86.0M 2026-06-17 $114.6M Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital 51 to 100 2022
Dioseve Dioseve produces egg cells using DIOLs to create more reproductive possibilities. Biotech Tokyo, Japan Series A $6.2M 2026-06-11 $15.5M ANRI, Coral Capital, Archetype Ventures +2 11 to 50 2021
Degron Therapeutics Degron Therapeutics discovers molecular glue degraders for cancer treatment. Biotech Shanghai, China Series A $40.0M 2026-05-14 $94.0M Baidu Ventures, BioVenture, New Alliance Capital +2 101 to 250 2021
Shanmu SHANMU Shanmu develops micro medical robots using digital microfluidic chipsets and artificial intelligence algorithms. Artificial intelligence Shenzhen, China Series A $14.7M 2026-05-06 $16.0M QF Capital, Hofan Venture, Wanwu Capital +1 1 to 10 2020
Scala Biodesign Scala Biodesign provides partners with a computational solution that increases the value of proteins and speeds their development. Artificial intelligence Tel Aviv, Israel Series A $16.0M 2026-03-31 $26.2M Intel Capital, Intel Ignite, TLV Partners 1 to 10 2022
Neurodome Neurodome manufactures non-invasive deep brain nerve modulation technology and products. Biotech Xian Shi, China Series A $14.5M 2026-03-12 $14.5M Shunwei Capital, Frees Fund, Oriza Holdings +2 11 to 50 2019
Celloid Celloid supplies a 3D cell culture medium that supports quality-controlled long-term cultivation of organoids. Biotech Seongnam, South Korea Series A $6.1M 2026-03-12 $7.9M FuturePlay, POSTECH Holdings 1 to 10 2021
iCamumo iCamumo develops off-the-shelf, general-purpose cell therapies using iPSCs. Biotech Suzhou, China Series A $14.4M 2026-03-09 $75.2M Delian Capital, West Lake Science and Technology Direct Investment Fund, Zhiyi Investment 51 to 100 2021
UniXell Biotechnology UniXell Biotechnology develops cell therapy drugs. Biotech Pudong, China Series A $7.2M 2026-02-11 $52.5M Hillhouse Investment, CDH Investments, Sherpa Healthcare Partners +1 11 to 50 2021
Xingsai Bio Xingsai Bio develops single-cell analysis instruments and related reagents and consumables. Biotech Qingdao Shi, China Series A $14.4M 2026-01-19 $28.3M Hengxu Capital, Haitang Fund, Neovision Capital +1 51 to 100 2014
Dishi Medical Dishi Medical manufactures ophthalmic medical devices and micro-assisted robots supported by biotechnology. Biotech Hangzhou, China Series A $13.7M 2026-01-19 $13.7M Hillhouse Investment, Fortune Venture Capital, Linear Capital +1 11 to 50 2021
Huixin Medical Valley Huixin Medical Valley develops cell therapies for neurological illnesses as a biopharmaceutical company. Biotech Changping, China Series A $14.3M 2026-01-07 $14.3M Green Pine Capital Partners, Jiuzhi Ziben, Beijing Venture Capital 51 to 100 2021
PRCXI Biotechnology PRCXI Biotechnology provides analytical instruments, bioinformatics, and automation solutions for life sciences. Biotech Suzhou, China Series A $14.0M 2025-12-31 $55.0M Qiming Venture Partners, SAIF Partners 101 to 250 2014
Allink Biotherapeutics Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. Biotech Shanghai, China Series A $47.0M 2025-12-16 $89.0M Legend Capital, Gaorong Capital, BioVenture +2 11 to 50 2023
Ningkang Ruizhu Ningkang Ruizhu develops targeted drugs. Biotech Zhuhai, China Series A $14.1M 2025-12-05 $25.6M GF Qianhe Investment, RiverHead Capital, Hanne Capital +1 11 to 50 2019
immunitoAI ImmunitoAI is a biotech platform that applies AI to antibody discovery and therapeutics. Biotech Bangalore, India Series A $6.1M 2025-11-25 $7.1M Pi Ventures 11 to 50 2020
Kunshi Biotechnology Kunshi Biotechnology develops drugs with an emphasis on solid tumor cells. Biotech Suzhou, China Series A $7.0M 2025-11-20 $7.0M Deshi Capital 51 to 100 2021
Brise Pharma Brise Pharma provides scientific research and technical services in the pharmaceutical field. Biotech Shanghai, China Series A $28.1M 2025-11-11 $228.3M Qiming Venture Partners, Sherpa Healthcare Partners, BioTrack Capital +1 11 to 50 2021
Primo Biotechnology Primo Biotechnology develops precision medicine and radioligand theranostics for cancer treatment. Artificial intelligence Taipei, Taiwan Series A $7.6M 2025-07-02 $14.1M AVA Angels 11 to 50 2023
Cure Stream Cure Stream develops an autonomous artificial pancreas system that uses an AI algorithm to decide hormone injections. Artificial intelligence Daegu, South Korea Series A $7.8M 2025-05-14 $7.8M TIPS Program 2019
Wimi bio Wimi Bio researches and develops gene editing and biological breeding technologies as a high-tech enterprise. Biotech Nanjing, China Series A $14.1M 2024-09-19 HosenCare Brothers 51 to 100 2017

Table 1. Biotech startups that raised Series A in Asia: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 721.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 MoleculeMind MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. Artificial intelligence Haidian, China Series A $86.0M 2026-06-17 $114.6M Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital 51 to 100 2022
2 Allink Biotherapeutics Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. Biotech Shanghai, China Series A $47.0M 2025-12-16 $89.0M Legend Capital, Gaorong Capital, BioVenture +2 11 to 50 2023
3 Degron Therapeutics Degron Therapeutics discovers molecular glue degraders for cancer treatment. Biotech Shanghai, China Series A $40.0M 2026-05-14 $94.0M Baidu Ventures, BioVenture, New Alliance Capital +2 101 to 250 2021
4 Remepy Remepy develops hybrid drugs that combine multiple therapeutic approaches for biotechnology research. Artificial intelligence Ramat Gan, Israel Series A $36.0M 2026-08-12 $51.0M Samsung NEXT, NFX, Vine Ventures +2 11 to 50 2022
5 Phil Rivers Technology Phil Rivers Technology provides AI solutions for pharmaceutical research and development. Artificial intelligence Beijing, China Series A $29.6M 2026-08-05 $57.3M Insight Capital 51 to 100 2015
6 Tianhu Technology Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. Artificial intelligence Minhang, China Series A $29.0M 2026-07-13 $54.2M Qiming Venture Partners, GSR United Capital, 3E Bioventures 11 to 50 2021
7 Scala Biodesign Scala Biodesign provides partners with a computational solution that increases the value of proteins and speeds their development. Artificial intelligence Tel Aviv, Israel Series A $16.0M 2026-03-31 $26.2M Intel Capital, Intel Ignite, TLV Partners 1 to 10 2022
8 Artivila Therapeutics Artivila Therapeutics uses artificial intelligence to discover new pharmaceutical drugs for patients. Artificial intelligence Shenzhen, China Series A $14.7M 2026-06-23 $53.3M Highlight Capital, Med-Fine Capital, Hike Capital +2 11 to 50 2018
9 Prime Lifescience Prime Lifescience develops a big data platform for life sciences research and analysis. Biotech Hangzhou, China Series A $14.7M 2026-06-30 $44.5M Qiming Venture Partners, Qiji Investment, Ennovation Ventures 11 to 50 2021
10 SynMetaBio SynMetaBio develops synthetic biological materials by combining synthetic biology with material design. Biotech Shanghai, China Series A $14.7M 2026-07-06 $16.1M MiraclePlus, Linear Capital, Danen Capital 11 to 50 2021

Table 2. Biotech startups that raised Series A in Asia: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 TIPS Program Startup incubator Gangneung, South Korea 6 1% 1 Apollon
2 BioVenture Venture capital firm Suzhou, China 6 1% 2 Degron Therapeutics, Allink Biotherapeutics
3 Qiming Venture Partners Venture capital firm Shanghai, China 5 1% 3 Tianhu Technology, Prime Lifescience, PRCXI Biotechnology
4 CDH Investments Private equity firm Kowloon City, Hong Kong 4 1% 1 UniXell Biotechnology
5 Gaorong Capital Venture capital firm Wangjing, China 3 0% 2 BioGeometry, Allink Biotherapeutics
6 KB Investment Private equity firm Seoul, South Korea 3 0% 1 Apollon
7 Legend Capital Venture capital firm Beijing, China 3 0% 2 Lingtai Krypton Biotechnology, Allink Biotherapeutics
8 ANRI Venture capital firm Tokyo, Japan 3 0% 2 Dioseve, Cosomil
9 Frees Fund Venture capital firm Beijing, China 3 0% 1 Neurodome
10 Shaanxi Investment Capital Venture capital firm Xian, China 3 0% 1 Neurodome
11 Hillhouse Investment Angel group Singapore 3 0% 2 UniXell Biotechnology, Dishi Medical
12 SZHTI Group Venture capital firm Shenzhen, China 3 0% 2 Newdel Biotech, JGene Biotechnology
13 Haitang Fund Venture capital firm Nankai, China 3 0% 1 Xingsai Bio
14 Taiyu Investment Venture capital firm Beijing, China 3 0%
15 Bluepoint Startup accelerator Daejeon, South Korea 3 0%

Table 3. Biotech startups that raised Series A in Asia: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 582 81% $7.0B
Software 61 8% $1.0B
Artificial intelligence 42 6% $975.8M
Hardware 26 4% $82.3M
Cybersecurity 9 1%
Energy 4 1% $61.8M
Commerce 3 0%
Fintech 3 0%
Education 2 0%

Table 4. Biotech startups that raised Series A in Asia by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series A 721 100% $8.1M

Table 5. Biotech startups that raised Series A in Asia by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
China 485 67%
South Korea 84 12%
Israel 42 6%
Japan 41 6%
Singapore 25 3%
India 17 2%
Taiwan 12 2%
Hong Kong 8 1%
Sri Lanka 3 0%
United Arab Emirates 1 0%
Malaysia 1 0%
Turkey 1 0%

Table 6. Biotech startups that raised Series A in Asia by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Shanghai 76 11%
Hangzhou 37 5%
Beijing 35 5%
Shenzhen 34 5%
Suzhou 32 4%
Seoul 30 4%
Nanjing 26 4%
Singapore 22 3%
Haidian 20 3%
Tokyo 16 2%
Guangzhou 14 2%
Chengdu 14 2%

Table 7. Biotech startups that raised Series A in Asia by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 4 3% $60.3M
October 2026 9 7% $91.2M
September 2026 6 5% $314.7M
August 2026 14 11% $198.9M
July 2026 15 12% $166.3M
June 2026 7 6% $171.4M
May 2026 12 9% $156.3M
April 2026 5 4% $55.7M
March 2026 7 6% $51.1M
February 2026 7 6% $39.7M
January 2026 18 14% $94.6M
December 2025 14 11% $196.3M
November 2025 9 7% $42.7M

Table 8. Biotech startups that raised Series A in Asia: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 104 14% $1.4B
2025 103 14% $975.1M
2024 96 13% $588.2M
2023 90 12% $860.1M
2022 69 10% $1.1B
2021 66 9% $923.3M

Table 9. Biotech startups that raised Series A in Asia by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 32 5%
2020 to 2022 221 31%
2015 to 2019 289 41%
2010 to 2014 98 14%
Before 2010 67 9%

Table 10. Biotech startups that raised Series A in Asia by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 101 17%
11 to 50 297 51%
51 to 100 96 16%
101 to 250 46 8%
251 to 500 21 4%
501 to 1,000 9 2%
1,001 to 5,000 9 2%
5,001 to 10,000 1 0%
10,001 or more 2 0%

Table 11. Biotech startups that raised Series A in Asia by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in Asia whose last round is Series A are on the list?
721, in the file dated 16 November 2026. 127 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 721 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series A in Asia: 721 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $349 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in Asia

Other sectors that raised Series A in Asia

Cite: FundingWatcher, 721 biotech companies in Asia whose most recent round is Series A, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-a/asia/